|Table of Contents|

Analysis of clinicopathological features,treatment,and prognostic factors of breast squamous cell carcinoma and breast adenosquamous carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 19
Page:
3593-3599
Research Field:
Publishing date:

Info

Title:
Analysis of clinicopathological features,treatment,and prognostic factors of breast squamous cell carcinoma and breast adenosquamous carcinoma
Author(s):
SU Xiaohan1; 2; LI Jinsui1; 2; TAN Qiao1; 2; HOU Lingmi1; 2; LI Junyan3
1.Department of Breast and Thyroid Surgery,Biological Targeting Laboratory of Breast Cancer,Academician(expert) Work Station,Affiliated Hospital of North Sichuan Medical College,Sichuan Nanchong 637000,China;2.Sichuan Key Laboratory of Medical Imaging,Sichuan Nanchong 637000,China;3.Chengdu Fifth People's Hospital,Sichuan Chengdu 610000,China.
Keywords:
breast cancer; squamous cell carcinoma; adenosquamous carcinoma; prognosis; SEER database
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.19.011
Abstract:
Objective:To investigate and compare the clinicopathological features,treatment and prognostic factors of squamous cell carcinoma of breast and adenosquamous carcinoma of breast.Methods:According to the inclusion and exclusion criteria,we extract the patient data of invasive ductal carcinoma(IDC),squamous cell carcinoma(SCC),and adenosquamous carcinoma(ASC) of the breast in 2000 to 2018 from The Surveillance,Epidemiology,and End Results(SEER) database of the National Cancer Institute of the United States.We analyze the clinicopathological characteristics and treatment differences of the population.Univariate and multivariate Cox regression models were used to evaluate breast cancer-specific survival(BCSS) and overall survival(OS) in SCC and ASC patients.Hazard ratio(HR)and 95% confidence interval(CI) were calculated.Propensity score matching(PSM) balanced confounding factors between groups,and survival curves were plotted using the Kaplan-Meier method.The difference in prognosis was analyzed by Log-rank test.Results:A total of 813 451 IDC, 579 SCC, and 397 ASC patients were included in the SEER database.In comparison, IDC showed an earlier age of diagnosis, smaller tumor diameter, earlier TNM stage, better histological grade, more Lumina subtypes, and better prognosis compared to SCC and ASC.Multivariate Cox regression analysis revealed that for SCC, age at diagnosis, race, T stage, N stage, M stage, and surgery method were independent prognostic factors for both BCSS and OS.Similarly, for ASC, age at diagnosis, T stage, and N stage were identified as independent prognostic factors for both BCSS and OS.Conclusion:Compared to IDC, SCC and ASC exhibit more aggressive behavior and have a worse prognosis.However, after accounting for confounding variables, IDC, SCC, and ASC show no significant difference in prognosis.The poorer prognosis observed in SCC and ASC is primarily attributed to the later tumor stage and a higher proportion of triple-negative subtypes, rather than the pathological type itself.It is important to note that the clinical treatment of SCC and ASC should be more standardized to optimize patient outcomes.

References:

［1］HENNESSY BT,KRISHNAMURTHY S,GIORDANO S,et al.Squamous cell carcinoma of the breast［J］.Journal of Clinical Oncology,2005,23(31)：7827-7835.
［2］PEZZI CM,PATEL-PAREKH L,COLE K,et al.Characteristics and treatment of metaplastic breast cancer:analysis of 892 cases from the National Cancer Data Base［J］.Annals of Surgical Oncology,2007,14(1)：166-173.
［3］PANDEY A,JOSHI K,MOUSSOURIS H,et al.Case reports on metaplastic squamous cell carcinoma of the breast and treatment dilemma［J］.Case Reports in Oncological Medicine,2019,2019:4307281.
［4］TAN QT,CHUWA EWL,CHEW SH,et al.Low-grade adenosquamous carcinoma of the breast:A diagnostic and clinical challenge［J］.International Journal of Surgery(London,England)2015,19:22-26.
［5］THORNLEY L,NAYLER S,BENN CA.Low-grade adenosquamous carcinoma of the breast［J］.The Breast Journal,2020,26(9)：1845-1846.
［6］ZHANG X,ZHANG B,ZANG F,et al.Clinical features and treatment of squamous cell carcinoma of the breast［J］.Onco Targets and Therapy,2016,9:3181-3185.
［7］AVIGDOR BE,BEIERL K,GOCKE CD,et al.Whole-exome sequencing of metaplastic breast carcinoma indicates monoclonality with associated ductal carcinoma component［J］.Clinical Cancer Research,2017,23(16)：4875-4884.
［8］PISCUOGLIO S,NG CKY,GEYER FC,et al.Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast［J］.NPJ Breast Cancer,2017,3:48.
［9］CHENG C,LUO Z,XIONG W,et al.Epidemiology and survival outcomes in adenosquamous carcinoma:a population-based study［J］.International Journal of Colorectal Disease,2022,37(7)：1581-1592.
［10］KAWAGUCHI K,SHIN SJ.Immunohistochemical staining characteristics of low-grade adenosquamous carcinoma of the breast［J］.The American Journal of Surgical Pathology,2012,36(7)：1009-1020.
［11］ZHU L,CHEN K.Clinicopathological features,treatment patterns,and prognosis of squamous cell carcinoma of the breast:an NCDB analysis［J］.BMC Cancer,2019,19(1)：26.
［12］YADAV S,YADAV D,ZAKALIK D.Squamous cell carcinoma of the breast in the United States:incidence,demographics,tumor characteristics,and survival［J］.Breast Cancer Research and Treatment,2017,164(1)：201-208.
［13］HAN Y,WANG J,XU B.Clinicopathological characteristics and prognosis of breast cancer with special histological types:A surveillance,epidemiology,and end results database analysis［J］.Breast(Edinburgh,Scotland),2020,54:114-120.
［14］BRANDT J,GARNE JP,TENGRUP I,et al.Age at diagnosis in relation to survival following breast cancer:a cohort study［J］.World Journal of Surgical Oncology,2015,13:33.
［15］WU HB,ZHANG AL,WANG W,et al.Expression of hormone receptors in low-grade adenosquamous carcinoma of the breast:A case report［J］.Medicine,2017,96(46)：e8785.
［16］HU J,LI G,ZHANG P,et al.A CD44v+ subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity［J］.Cell Death & Disease,2017,8(3)：e2679.
［17］HU JUN,CHENG NI, ZHONG ZHANQIANG,et al.CD44v6 regulates the growth of glioma cells through the Akt signaling pathway［J］.Modern Oncology,2018,26(19):3021-3025.
［18］LEI T,PU T,WEI B,et al.Clinicopathologic characteristics of HER2-positive metaplastic squamous cell carcinoma of the breast［J］.Journal of Clinical Pathology,2022,75(1)：18-23.
［19］LEI R,MIAO L.Primary squamous cell carcinoma of the breast:report of two cases with HER2 overexpression［J］.Cancer Biology & Therapy,2020,21(12)：1081-1086.
［20］WHALEY RD,ALDREES R,DOUGHERTY RE,et al.Breast implant capsule-associated squamous cell carcinoma:report of 2 patients［J］.International Journal of Surgical Pathology,2022,30(8)：900-907.
［21］BEHRANWALA KA,NASIRI N,ABDULLAH N,et al.Squamous cell carcinoma of the breast:clinico-pathologic implications and outcome［J］.European Journal of Surgical Oncology,2003,29(4)：386-389.
［22］XU C,GU Z,LIU J,et al.Adenosquamous carcinoma of the breast:a population-based study［J］.Breast Cancer(Tokyo,Japan)2021,28(4)：848-858.
［23］COCHRANE K,BELL JL,HEIDEL RE,et al.Adenosquamous carcinoma of the breast,an uncommon diagnosis with poor prognosis-lessons learned from a 12-year analysis of the National Cancer Database［J］.The Breast Journal,2021,27(2)：165-169.

Memo

Memo:
四川省自然科学基金面上项目（编号：2022NSFSC0775）;四川省中医药管理局中医药基础项目（编号：2020JC0055）；四川省南充市市校合作科研创新团队建设专项(编号：20SXCXTD0001)
Last Update: 2023-08-31